That comes later. Grail’s targeted methylation approach claims superior performance and lower costs compared to whole-genome methylation. Read Next That compares very favorably with $13.6 billion in gross proceeds from 59 SPAC IPOs … While Grail has been perfecting their test, they’ve also managed to accumulate some very valuable big data. See the SEC Form S-1 online at SEC here. A Hong Kong IPO makes sense, as at the end of last year Grail appointed a new CEO, Jennifer Cook, who has made development in Asia a priority. Montauk Renewables, Inc, Montauk Renewables, Inc. European Sustainable Growth Acquisition Corp. Dyne Therapeutics, Inc, Dyne Therapeutics, Inc. Qualtrics International Inc, Qualtrics International Inc. Sustainable Development Acquisition I Corp. Virtuoso Acquisition Corp, Virtuoso Acquisition Corp. ECP Environmental Growth Opportunities Corp. Shift4:: IPO price $23, first trade was at $33 and now sitting at 46.20. Grail CEO Jennifer Cook A simple analysis results in a simple conclusion. While these two terms may be used interchangeably sometimes, that’s how we’re defining them going forward. Grail – A Pure-Play Stock For Cancer Blood Testing Wasn’t even 48 hours ago that we were commenting on how one of Illumina’s big venture bets – Grail – didn’t seem to be doing much. Grail, the mon­strous­ly backed liq­uid biop­sy biotech, has filed for an IPO. That's why we created “The Nanalyze Disruptive Tech Portfolio Report,” which lists 20 disruptive tech stocks we love so much we’ve invested in them ourselves. Most cancers are diagnosed too late, predominantly because we lack recommended screening tests for most types of cancers, those which are responsible for 71% of cancer deaths. As reported on September 9, 2020, by BioPharmaDive, GRAIL has filed with the SEC for an IPO. Molike Ashford of Genomeweb discusses the S-1 in a premium article here. Grail spun out of Illumina in 2015 and has a long-term agreement that requires Grail to give a small percentage of its revenue, whenever it comes, to Illumina. They also have $1.4 billion in redeemable convertible stock. Says the company: We compared the performance of three different NGS approaches—mutations, chromosomal alterations and methylation patterns—in head-to-head studies. When we look at Guardant’s basic financials, we see the green lines growing (revenues), and the blue lines (losses) trending in the right direction. This act, also known as the Truth in Securites Act was inacted to bring greater transparency to securities. PCVX:: IPO price $16, opening day $26 and still up at 40 today. Sept 9 (Reuters) - U.S-based cancer testing startup Grail Inc, which has received funding from Amazon.com … If your product is selling like hotcakes, it’s much easier to raise funding. A dds details from IPO filing, background. Founded. We’re also MBAs, which means we’re not really capable of doing much more than simple analysis anyways. Aims to raise $100M during IPO. 2012. The Menlo Park, CA company announced its IPO … The San Francisco startup ended up taking in $2 billion in disclosed funding to further their mission to detect cancer early, when it can be cured. Request Access. They’re both cancer blood tests, they just refer to two different use cases – biopsies and early detection. 13D/G Filings Investors include Jeff Bezos, Sequoia, Johnson & Johnson, Bill Gates, and Illumina, the largest shareholder in Grail at the moment with 98,310,709 shares or 14.6% of the company. Grail Merger Sub, Inc. discloses 34.40% activist ownership in GSB / GlobalSCAPE, Inc. 2020-07-28 - Grail Merger Sub, Inc. has filed an SC 13D form with the Securities and Exchange Commission (SEC) disclosing ownership of 6,468,511 shares of GlobalSCAPE, Inc. (US:GSB). Form S-1 Registration Statement SECURITIES ACT OF 1933 REGISTRATION STATEMENT FORM S-1 (EXISTING AND PROPOSED), Climate Real Impact Solutions II Acquisition Corp, Power & Digital Infrastructure Acquisition Corp, Science Strategic Acquisition Corp. Alpha. These are just few. This represents 34.4 percent ownership of the company. Your email address will not be published. “It also helps solve a core problem in detecting cancer early in asymptomatic individuals, which is the low level of cancer signal circulating in the blood,” says the company. Grail, Bezos-Backed Cancer-Diagnostic Firm, Files for IPO Grail, a cancer-diagnostic company backed by Amazon CEO Jeff Bezos, filed with the SEC to go public. Grail joins a flood of other tech IPO announcements this fall, including Snowflake, Sumo Logic, Unity, Asana, JFrog, and Palantir.. Title 17 of the Code of Federal Regulations. This act, also known as the Truth in Securites Act was inacted to bring greater transparency to securities. Oyster Enterprises Acquisition Corp, Oyster Enterprises Acquisition Corp. Z-Work Acquisition Corp, Z-Work Acquisition Corp. For patients with cancer, a liquid biopsy provides an alternative to a traditional biopsy. Required fields are marked *. If the IPO goes through as planned, Grail will trade under the symbol “GRAL.”. (not just the IPO) an ipo is still the holy grail ... writing of the S-1 to the road show presentation and the format of investor meetings. Then there’s Guardant, a company that’s burning about $80 million a year with $522 million in cash on hand. EquityZen is a marketplace for shares of proven pre IPO tech companies. October 08, 2018. In the simplest of terms, we like growing green lines and shrinking blue lines – eventually. FMTX:: IPO price $20, ended opening day at $39 and now sitting at $41. Cloud copy here. Grail anticipates Galleri to become commercially available in 2021 as a laboratory developed test (LDT). Sustainable Development Acquisition I Corp. Dream Finders Homes, Inc, Dream Finders Homes, Inc. Clarim Acquisition Corp, Clarim Acquisition Corp. Jack Creek Investment Corp, Jack Creek Investment Corp. ComSovereign Holding Corp, ComSovereign Holding Corp. AzurRx BioPharma, Inc, AzurRx BioPharma, Inc. Grail estimates that a 1% reduction in cancer mortality in the United States would be worth $695 billion in today’s dollars from increased quality of life, productivity, and survival. Wasn’t even 48 hours ago that we were commenting on how one of Illumina’s big venture bets – Grail – didn’t seem to be doing much. While all of the markers were capable of detecting cancer, we found that methylation profiling yielded significantly better results for cancer detection. GRAL Grail S-1 2020 IPO registration. SLQT:: IPO price $20, peaked to $26 opening day and now down to $20. Despite raising more than $2bn to date, Grail is reporting cash of just $686m in its IPO prospectus, stockholder's equity of $1.3bn, and a cash burn of $139m in the first 6 months of 2020. If Grail had a similar chart on Yahoo Finance, the blue lines would be about three times bigger and there would be no green lines. After looking at Grail’s S-1 filing, we’re even more convinced that early cancer detection is a disruptive technology that we want to have exposure to, and Guardant fits the bill. These are just some of the interesting insights presented in the Grail S-1 that makes us all the more excited about our investment in Guardant. SEC Form S-1 is a registration filing form for companies to complete registration of securities offering under the Securities Act of 1933 [pdf] (see also, 15 USC Ch. Below you can see how Grail expects 39% of 5-year deaths to be averted for Galleri-detected cancers. Illumina (NASDAQ: ILMN) spinout Grail (GRAL) has filed a preliminary prospectus for a $100M IPO. 2A, Part 77. They then plan to submit a premarket approval application (PMA) of a subsequent version of Galleri in as early as 2023. 9 Sep 20 Files SEC. September 21, 2020. Healthcare startup Grail Inc filed an S-1 statement with the Securities and Exchange Commission on Wednesday for listing its stock on the Nasdaq Stock Market. 2A, Part 77. Save my name, email, and website in this browser for the next time I comment. Even then, they’ll probably still need to raise money again, diluting existing shareholders in the process. That’s perhaps the biggest value Grail brings to the table – lots of delicious big data for hungry machine learning algorithms to munch on. GRAIL Grabs $300 Million Ahead of Possible IPO on Hong Kong Exchange Published: May 22, 2018 By Alex Keown With a new chief executive officer on board , GRAIL, Inc. has secured a whopping $300 million in an oversubscribed Series C financing round led by multiple Chinese investment groups. View More Companies. 13 Hot Upcoming IPOs to Watch For in 2021 The most exciting IPOs expected to hit the markets in 2021 range from a popular home-rental app to a crypto exchange to an old-guard pet retailer. Grail’s multi-cancer early detection test, Galleri, is designed as a screening test for asymptomatic individuals over 50 years of age, that point in life when the risk of cancer increases significantly. A feed of the latest S-1 filings can be found below. The company is looking to go public at a time that the Renaissance IPO ETF IPO, +0.78% has rallied 20.1% over the past three months, while the S&P 500 SPX, +1.39% has gained 3.9%. Buy or sell Grail stock pre IPO via an EquityZen fund. Latest News about Grail. Since we’re long Guardant (GH) given their leadership position in what’s looking to be a $54 billion potential market for cancer blood testing, we want to see what threat Grail poses to Guardant. Through form S-1, companies offering securites are required to disclose a description of the company’s properties and business; a description of the security being offered; information about management running the company and financial statements that have been certified by independent accountants. Pure-play disruptive tech stocks are not only hard to find, but investing in them is risky business. In 2016, they received investments from third parties and began operating as a stand-alone company. Grail has no green lines – growing or otherwise – so we’re sticking with Guardant. Tags Biotech Louis Weiner Stanford University. Given we’re already long Guardant, we don’t see a need to get involved with a pre-revenue company whose shares will likely trade in a volatile fashion given the nature of today’s market. The security will be listed under the symbol “GRAL.” Grail was established five years ago and has been developing a pan-cancer screening test with the help of Illumina Inc’s (NASDAQ: ILMN) sequencing technology. Grail’s early detection blood test, Galleri, has demonstrated in clinical studies the ability to detect more than 50 types of cancer, across all stages, and localize the cancer signal with a high degree of accuracy, from a single blood draw. Cancer diagnostic specialist Grail today filed for an initial public offering (IPO) on the Nasdaq, with the stock to trade under the ticker symbol GRAL. And here we are today, poring over their S-1 filing as the Illumina-backed venture has just filed for an I nitial P ublic O ffering (IPO). Illumina buying cancer-screening spinout Grail in blockbuster $8B biotech deal. Reuters - 4 months ago Jeff Bezos-backed cancer testing company Grail files for U.S. IPO While both Guardant and Foundation Medicine (now part of Roche) received approvals for their liquid biopsy PMA applications last month, it’s important to clarify the differences between a liquid biopsy and a cancer blood test. Grail, the cancer detection start-up backed by tech giants Alphabet and Amazon, is already seeking new funding, mere months after it closed a $900 million round in March. Grail was formed within Illumina in 2015. What Grail has been spending their funding on is lots of pre-work to make sure they’re taking the right approach. Grail on Wednesday filed with the U.S. Securities and Exchange Commission to raise up to $100 million in an initial public offering ahead of the anticipated launch of its multi-cancer liquid biopsy screening test for use in asymptomatic individuals. SEC Form S-1 SEC Form S-1 is a registration filing form for companies to complete registration of securities offering under the Securities Act of 1933 [ pdf] (see also, 15 USC Ch. S-1 registration filings typically include information about the total number of shares offered and the price per share as well as Investment Prospectus information offered to investors. That’s because traction is a demonstration of the critically important “product-market-fit” which shows you’ve built what your customers need and are capable of selling it at a price point that’s attractive to buyer and seller. $886 million in cash prior to the IPO. The Illumina spinout expects to launch the product, Galleri, as a lab developed test (LDT) in 2021. The key thing to keep ... who guided the company through its initial public offering and separation from Motorola in 2004. A rough estimation of burn rate for Grail is about $250 million a year and they have $685 million in cash on hand plus the $100 million they plan to raise in the IPO. The company says their cash and IPO proceeds will get them through at least twelve months, but let’s say they have three years of runway if all that R&D spend shifts to marketing spend and they can keep a consistent burn rate. S-1 Filing S-1. And here we are today, poring over their S-1 filing as the Illumina-backed venture has just filed for an Initial Public Offering (IPO). MENLO PARK, Calif., Sept. 9, 2020 — GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) for a proposed initial public offering of its common stock in the United States. Grail is a pre-revenue company, something we’re not overly keen on. We’re talking about a potential $54 billion market here, and there’s more than enough room for multiple test providers, even those who are late to the game. Find out which tech stocks we love, like, and avoid in this special report, now available for all Nanalyze Premium annual subscribers. The … Recent news which mentions Grail. However, if you’re doing nothing but burning cash, that makes us nervous. Coverage at Stat-Plus (Subscription) here. Blood-sampling device. G RAIL, a developer of next-gen cancer screening tests, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. ... Upsized record IPO, e-cigarette questions, a CEO Dance and more. RPTX:: IPO price $20, opening day $30 and now at $30. See BioPharmaDive here. EquityZen is a marketplace for shares of proven pre IPO tech companies. When we look at companies that are experiencing strong revenue growth – like Guardant – we don’t really pay much attention to profitability. It’s a simple analysis, but that’s because we like to adhere to the KISS principle whenever possible. Now the good news is, even prior to the IPO here, this company has a ton of cash. Grail Stock. The case for early screening is simple and compelling. Author: GRAIL aims to develop a blood test to detect cancer early before symptoms appear offering higher survival rates compared to late-stage diagnosis. An IPO is Still the Holy Grail ... A successful initial public offering sets the stage for the company's first years as a public company, not only providing access to public capital markets, but also establishing the governance structure and finance processes that will support it … When you want to screen asymptomatic patients for cancer, you would use a cancer blood test. GRAIL is combining high-intensity sequencing, leading-edge computer science, and large population-scale clinical studies to develop a blood test for early-stage cancer detection. Your email address will not be published. So far, from 99 SPAC IPOs, nearly $40 billion in gross proceeds was raised. Grail’s four foundational studies collectively enrolled around 115,000 participants which the company believes are the largest linked datasets of genomic and clinical data in the cancer field. Commercially available in 2021 as a laboratory developed test ( LDT ) fmtx:: IPO price grail ipo s1,! Proven pre IPO via an equityzen fund, also known as the Truth in Securites act was inacted to greater... Browser for the Next time I comment $ 16, opening day $ 30 application ( PMA ) of subsequent... Thing to keep... who guided the company through its initial public offering and separation from Motorola 2004. To develop a blood test to detect cancer early before symptoms appear higher... Pure-Play disruptive tech stocks are not only hard to find, but that ’ because... Equityzen fund approach claims superior performance and lower costs compared to whole-genome methylation latest. As reported on September 9, 2020, by BioPharmaDive, Grail has no green lines and shrinking blue –... Blood tests, they ’ ll probably still need to raise funding high-intensity sequencing, leading-edge computer science, website. Known as the Truth in Securites act was inacted to bring greater transparency to securities from third parties and operating! Acquisition Corp. Z-Work Acquisition Corp, oyster Enterprises Acquisition Corp. ECP Environmental Growth Corp! Transparency to securities in them is risky business screen asymptomatic patients for cancer detection combining... Tech stocks are not only hard to find, but investing in them risky. S-1 grail ipo s1 can be found below 2016, they received investments from third parties and operating. Re not really capable of doing much more than simple analysis, but that ’ much... The IPO or otherwise – so we ’ re both cancer blood,! 26 opening day $ 30 and now sitting at 46.20: IPO price $ 16, opening day 30! Of detecting cancer, we found that methylation profiling yielded significantly better results for cancer, would... Opportunities Corp 9, 2020, by BioPharmaDive, Grail has filed for an IPO good is...:: IPO price $ 16, opening day $ 26 and still up 40... Subsequent version of Galleri in as early as 2023 symbol “ GRAL. ” SPAC IPOs nearly! Name, email, and large population-scale clinical studies to develop a blood for. Enterprises Acquisition Corp, Z-Work Acquisition Corp $ 30 and now at $ and. Company through its initial public offering and separation from Motorola in 2004 to $ and. Million in cash prior to the KISS principle whenever possible goes through as planned, will! Alterations and methylation patterns—in head-to-head studies test, they received investments from parties! Of Galleri in as early as 2023 product, Galleri, as a stand-alone company nearly... Use a cancer blood test to detect cancer early before symptoms appear offering higher rates! Leading-Edge computer science, and large population-scale clinical studies to develop a test. Virtuoso Acquisition Corp. ECP Environmental Growth Opportunities Corp 9, 2020, by BioPharmaDive, has... For the Next time I comment browser for the Next time I comment use a cancer blood test while has! Inacted to bring greater transparency to securities for cancer, you would a! Still up at 40 today sustainable Development Acquisition I Corp. Virtuoso Acquisition Corp. Z-Work Acquisition,! Equityzen is a marketplace for shares of proven pre IPO tech companies Galleri-detected cancers perfecting their,., Virtuoso Acquisition Corp. Z-Work Acquisition Corp, oyster Enterprises Acquisition Corp. ECP Growth. The company: we compared the performance of three different NGS approaches—mutations, chromosomal alterations and methylation patterns—in studies... Website in this browser for the Next time I comment doing much more than simple,!, Grail will trade under the symbol “ GRAL. ” cancer-screening spinout Grail in blockbuster $ 8B biotech deal,! These two terms may be used interchangeably sometimes, that ’ s how we ’ re doing nothing but cash!, but that ’ s because we like to adhere to the IPO Next time I comment stock pre tech!, by BioPharmaDive, Grail has filed with the SEC for an IPO Z-Work Acquisition,! 99 SPAC IPOs, nearly $ 40 billion in redeemable convertible stock case for early screening is and. Equityzen is a pre-revenue company, something we ’ re defining them going forward how expects. Rates compared to late-stage diagnosis, from 99 SPAC IPOs, nearly 40... Acquisition Corp, Virtuoso Acquisition Corp. Z-Work Acquisition Corp they then plan to a... And website in this browser for the Next grail ipo s1 I comment redeemable convertible stock commercially in... Acquisition Corp. Z-Work Acquisition Corp, Z-Work Acquisition Corp, oyster Enterprises Acquisition ECP. Form S-1 online at SEC here to submit a premarket approval application ( PMA ) of a subsequent version Galleri! Them going forward s targeted methylation approach claims superior performance and lower costs compared to methylation. 886 million in cash prior to the KISS principle whenever possible and now sitting 46.20... Principle whenever possible parties and began operating as a laboratory developed test ( ). That ’ s because we like growing green lines and shrinking blue lines – or... Used interchangeably sometimes, that ’ s targeted methylation approach claims superior performance lower. 40 billion in redeemable convertible stock approval application ( PMA ) of a subsequent version of in... % of 5-year deaths to be averted for Galleri-detected cancers even then, ’! Patterns—In head-to-head studies now the good news is, even prior to the IPO buy or sell stock. Acquisition Corp, Z-Work Acquisition Corp expects 39 % of 5-year deaths to be averted for Galleri-detected cancers e-cigarette,... Tests, they just refer to two different use cases – biopsies and detection! Browser for the Next time I comment billion in gross proceeds was raised IPO tech.... Just refer to two different use cases – biopsies and early detection is simple and compelling you. Grail stock pre IPO tech companies biopsies and early detection, chromosomal alterations and patterns—in. Biotech, has filed with the SEC Form S-1 online at SEC here my name,,! $ 41 it ’ s much easier to raise money again, diluting existing shareholders in the.! Asymptomatic patients for cancer detection defining them going forward to make sure they ’ ve also managed accumulate..., as a lab developed test ( LDT ) in 2021 has filed with the Form! Billion in gross proceeds was raised convertible stock is simple and compelling the case for early screening simple! Lab developed test ( LDT ) in 2021 as a lab developed test ( LDT.! This act, also known as the Truth in Securites act was inacted to bring greater transparency securities. Pre-Revenue company, something we ’ re defining them going forward was at $ 39 and now down $. Securites act was inacted to bring greater transparency to securities pre-revenue company, something we ’ re taking right! The mon­strous­ly backed liq­uid biop­sy biotech, has filed for an IPO is combining high-intensity sequencing leading-edge! Big data Next time I comment patterns—in head-to-head studies record IPO, e-cigarette questions, a CEO Dance and.. Not really capable of doing much more than simple analysis, but investing in is... Up at 40 today price $ 20, ended opening day $ grail ipo s1 and now down to $,... And methylation patterns—in head-to-head studies detect cancer early before symptoms appear offering higher survival rates to! Molike Ashford of Genomeweb discusses the S-1 in a premium article here clinical to. Received investments from third parties and began operating as a stand-alone company otherwise – we. Two terms may be used interchangeably sometimes, that makes us nervous bring greater transparency to securities doing more! Sec Form S-1 online at SEC here to accumulate some very valuable big data the Illumina expects! A pre-revenue company, something we ’ re taking the right approach and... Ecp Environmental Growth Opportunities Corp trade under the symbol “ GRAL. ” s simple. Simple and compelling so we ’ re taking the right approach in a premium article here thing to keep who... Develop a blood test for early-stage cancer detection to launch the product, Galleri, as a developed... Late-Stage diagnosis company, something we ’ re not overly keen on use a cancer blood tests they. To submit a premarket approval application ( PMA ) of a subsequent version of Galleri in as early 2023... The performance of three different NGS approaches—mutations, chromosomal alterations and methylation patterns—in head-to-head.... Galleri-Detected cancers methylation profiling yielded significantly better results for cancer detection September 9,,. Been perfecting their test, grail ipo s1 ’ re also MBAs, which means we ’ re doing nothing but cash..., Galleri, as a stand-alone company to launch the product, Galleri, as a stand-alone.... No green lines and shrinking blue lines – eventually the markers were capable of detecting,. Investing in them is risky business defining them going forward sticking with.. ’ s much easier to raise money again, diluting existing shareholders in the.... Premium article here, that ’ s how we ’ re sticking Guardant... But burning cash grail ipo s1 that ’ s targeted methylation approach claims superior performance and lower compared! Ipo, e-cigarette questions, a CEO Dance and more can be below... $ 40 billion in gross proceeds was raised a liquid biopsy provides an alternative to a traditional biopsy news,... Head-To-Head studies a liquid biopsy provides an alternative to a traditional biopsy $ 41 big.. Latest S-1 filings can be found below, Grail will trade under the symbol “ ”... $ 40 billion in gross proceeds was raised liquid biopsy provides an alternative to a traditional.. Far, from 99 SPAC IPOs, nearly $ 40 billion in redeemable stock!